These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14470006)

  • 21. [Remarks on the use of heparin and neutralizing agents in extracorporeal circulation].
    GANORA HM; LAMBERTINI A; BUGNARD E
    Sem Med; 1962 Oct; 121():1470-4. PubMed ID: 13946406
    [No Abstract]   [Full Text] [Related]  

  • 22. [THE MECHANISM OF SO-CALLED "HEPARIN REBOUND" AFTER EXTRACORPOREAL CIRCULATION].
    BROEGLI H
    Thromb Diath Haemorrh; 1965 Jun; 13():401-17. PubMed ID: 14347864
    [No Abstract]   [Full Text] [Related]  

  • 23. [Value of the determination of activated coagulation time for decreasing heparin and protamine sulfate doses during operations with artificial circulation].
    Savina ME; Piatnitskaia GK; Kukaeva EA; Charnaia MA; Charnyĭ ISh
    Anesteziol Reanimatol; 1981; (5):52-6. PubMed ID: 7325386
    [No Abstract]   [Full Text] [Related]  

  • 24. [THE USE OF THROMBOELASTOGRAPHY IN THE STUDY OF BLOOD COAGULATION DURING EXTRACORPOREAL CIRCULATION. PRELIMINARY CONTRIBUTION].
    TUCCI G; TOMAI F
    Ann Ital Chir; 1963; 40():1112-29. PubMed ID: 14158511
    [No Abstract]   [Full Text] [Related]  

  • 25. The management of abnormal bleeding following extracorporeal circulation.
    PERKINS HA; OSBORN JJ; GERBODE F
    Ann Intern Med; 1959 Oct; 51():658-67. PubMed ID: 14431856
    [No Abstract]   [Full Text] [Related]  

  • 26. Blood clotting problems in extracorporeal circulation.
    MATZKE J; JENSEN RS; RYGG IH
    Acta Chir Scand; 1961 Oct; 122():208-16. PubMed ID: 14471494
    [No Abstract]   [Full Text] [Related]  

  • 27. [ON SOME FEATURES OF ARTIFICIAL BLOOD CIRCULATION].
    SKORIK VI; BALLIUZEK FV; DZUTSOV NK; KARIMOVA TV
    Patol Fiziol Eksp Ter; 1964; 8():39-45. PubMed ID: 14181938
    [No Abstract]   [Full Text] [Related]  

  • 28. [Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time].
    Kessler G; Grünes G
    Anaesthesist; 1984 Dec; 33(12):588-91. PubMed ID: 6528961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [TRANSFUSION PROBLEMS PRESENTED BY EXTRACORPOREAL CIRCULATION. PREPARATION OF THE BLOOD AND CONTROL OF COAGULATION].
    JAULMES B; TERRIER E; SPROVIERI L; CARIGNANI G; PRIGENT C; DUBOST C
    Bibl Haematol; 1964; 19():118-29. PubMed ID: 14266982
    [No Abstract]   [Full Text] [Related]  

  • 30. [Heparin and protamine in extracorporeal circulation].
    SATTER P
    Thoraxchirurgie; 1961 Feb; 8():499-503. PubMed ID: 13746734
    [No Abstract]   [Full Text] [Related]  

  • 31. EVALUATION OF PROTAMINE AND HEXADIMETHRINE BROMIDE AS ANTIHEPARIN AGENTS IN EXTRACORPOREAL CIRCULATION.
    GUPTA S; BANERJEE C; BASU AK
    J Indian Med Assoc; 1963 Sep; 41():231-6. PubMed ID: 14063345
    [No Abstract]   [Full Text] [Related]  

  • 32. Behaviour of the antithrombin time after extracorporeal circulation of blood.
    THIES HA
    Thromb Diath Haemorrh; 1960 Jun; 4():400-9. PubMed ID: 13837841
    [No Abstract]   [Full Text] [Related]  

  • 33. [FIBRINOLYSIS IN EXTRACORPOREAL CIRCULATION; ITS CAUSE AND TREATMENT].
    SUNADA T; SHIMIZU H; KAWAI S; KITAMURA H; MORIMOTO S; SHIGEMOTO H; TSUDA K; ONO I; NAKAYA R
    Rinsho Geka; 1964 Feb; 19():178-84. PubMed ID: 14135265
    [No Abstract]   [Full Text] [Related]  

  • 34. [Comparison of two schemes of administering the Russian protamine sulfate after extracorporeal circulation in cardiosurgical patients].
    Charnaia MA; Morozov IuA; Gladysheva VG; Isaeva AM
    Anesteziol Reanimatol; 2006; (5):31-3. PubMed ID: 17184058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Importance of constant biological control during extracorporeal circulation. I. Biological supervision of hemostasis].
    van der GHINST ; MASCART P
    Acta Chir Belg; 1962 May; 61():456-67. PubMed ID: 13947485
    [No Abstract]   [Full Text] [Related]  

  • 36. [The effect of protamine sulfate on blood coagulation in intravenous administration of placental extract].
    Skipetrov VP
    Patol Fiziol Eksp Ter; 1966; 10(4):69-70. PubMed ID: 5237748
    [No Abstract]   [Full Text] [Related]  

  • 37. Preliminary results of the reptilase clotting time and protamine test in patients undergoing open heart surgery with extracorporeal circulation.
    Palester-Chlebowczyk M; Strzyzewska E; Latallo ZS
    J Clin Pathol; 1972 Jul; 25(7):625. PubMed ID: 4672236
    [No Abstract]   [Full Text] [Related]  

  • 38. COAGULATION STUDIES IN EXTRACORPOREAL CIRCULATION.
    DYBKJAER E; BERG E; KISSMEYER-NIELSEN F
    Acta Chir Scand; 1964 Oct; 128():350-61. PubMed ID: 14211290
    [No Abstract]   [Full Text] [Related]  

  • 39. [Protamine dosage for heparin neutralization in open-heart surgery (author's transl)].
    Shiao K
    Fukuoka Igaku Zasshi; 1974 Nov; 65(11):878-88. PubMed ID: 4477114
    [No Abstract]   [Full Text] [Related]  

  • 40. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
    Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
    Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.